| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Heart Failure | 42 | 2020 | 6638 | 2.32 | Why? |
| Cardiology | 18 | 2020 | 2873 | 1.55 | Why? |
| Societies, Medical | 15 | 2020 | 6907 | 1.14 | Why? |
| Cyclooxygenase 2 Inhibitors | 3 | 2017 | 48 | 0.99 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2020 | 1454 | 0.76 | Why? |
| Cardiac Resynchronization Therapy | 5 | 2018 | 191 | 0.73 | Why? |
| Takotsubo Cardiomyopathy | 6 | 2019 | 453 | 0.68 | Why? |
| Diagnostic Techniques, Cardiovascular | 1 | 2018 | 144 | 0.66 | Why? |
| Blood Pressure | 9 | 2018 | 2198 | 0.66 | Why? |
| Stroke Volume | 9 | 2019 | 2153 | 0.66 | Why? |
| Ranibizumab | 1 | 2017 | 103 | 0.65 | Why? |
| Cardio-Renal Syndrome | 1 | 2018 | 68 | 0.65 | Why? |
| Edema | 1 | 2020 | 333 | 0.65 | Why? |
| Fabry Disease | 1 | 2018 | 106 | 0.64 | Why? |
| Heart Transplantation | 6 | 2019 | 1293 | 0.63 | Why? |
| Bevacizumab | 1 | 2017 | 149 | 0.62 | Why? |
| Wet Macular Degeneration | 1 | 2017 | 102 | 0.62 | Why? |
| Hemodynamics | 4 | 2019 | 1562 | 0.54 | Why? |
| Mitral Valve Insufficiency | 1 | 2017 | 302 | 0.51 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2017 | 604 | 0.50 | Why? |
| Heart-Assist Devices | 2 | 2018 | 812 | 0.49 | Why? |
| Patient Transfer | 1 | 2019 | 898 | 0.46 | Why? |
| Consensus | 5 | 2019 | 6345 | 0.45 | Why? |
| Acetaminophen | 1 | 2012 | 326 | 0.39 | Why? |
| Maltose | 2 | 2020 | 50 | 0.39 | Why? |
| Anticholesteremic Agents | 1 | 2011 | 186 | 0.38 | Why? |
| Cognition | 1 | 2017 | 1394 | 0.36 | Why? |
| Ventricular Function, Left | 6 | 2020 | 1555 | 0.35 | Why? |
| Endothelium, Vascular | 3 | 2020 | 1751 | 0.35 | Why? |
| Ferric Compounds | 2 | 2020 | 136 | 0.35 | Why? |
| Diuretics | 3 | 2019 | 326 | 0.35 | Why? |
| Celecoxib | 2 | 2017 | 49 | 0.34 | Why? |
| Atrial Natriuretic Factor | 2 | 2017 | 75 | 0.34 | Why? |
| Defibrillators, Implantable | 4 | 2017 | 624 | 0.33 | Why? |
| Quinolines | 1 | 2011 | 403 | 0.33 | Why? |
| Hypertension | 5 | 2019 | 8895 | 0.32 | Why? |
| Coronary Artery Disease | 7 | 2019 | 2570 | 0.30 | Why? |
| Retinal Vessels | 2 | 2018 | 255 | 0.29 | Why? |
| Europe | 18 | 2020 | 12702 | 0.28 | Why? |
| Magnetic Resonance Imaging | 2 | 2020 | 6551 | 0.27 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.27 | Why? |
| Switzerland | 7 | 2020 | 2738 | 0.26 | Why? |
| Myocardial Ischemia | 2 | 2020 | 781 | 0.25 | Why? |
| Double-Blind Method | 7 | 2020 | 5988 | 0.24 | Why? |
| Aorta | 2 | 2019 | 355 | 0.24 | Why? |
| Disease Management | 6 | 2020 | 6841 | 0.23 | Why? |
| Coronary Vessels | 2 | 2021 | 914 | 0.23 | Why? |
| Registries | 9 | 2020 | 12327 | 0.23 | Why? |
| Follow-Up Studies | 13 | 2019 | 17020 | 0.22 | Why? |
| Anemia, Iron-Deficiency | 2 | 2020 | 210 | 0.21 | Why? |
| Microcirculation | 3 | 2019 | 447 | 0.21 | Why? |
| Brain | 1 | 2017 | 5133 | 0.21 | Why? |
| Acute Disease | 9 | 2018 | 6029 | 0.21 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 5002 | 0.20 | Why? |
| Retinal Artery | 1 | 2019 | 16 | 0.20 | Why? |
| Cardiomyopathy, Hypertrophic | 2 | 2019 | 193 | 0.20 | Why? |
| Cardiomyopathy, Restrictive | 1 | 2019 | 30 | 0.19 | Why? |
| Myoblasts | 1 | 2018 | 24 | 0.19 | Why? |
| Hospitals | 1 | 2019 | 11793 | 0.19 | Why? |
| Polyarteritis Nodosa | 1 | 2018 | 25 | 0.19 | Why? |
| Sirtuin 3 | 1 | 2018 | 14 | 0.19 | Why? |
| Acetazolamide | 1 | 2018 | 27 | 0.19 | Why? |
| Pulmonary Wedge Pressure | 2 | 2017 | 53 | 0.19 | Why? |
| Vascular Stiffness | 2 | 2019 | 264 | 0.19 | Why? |
| Heart Rate | 2 | 2018 | 1527 | 0.18 | Why? |
| alpha-Galactosidase | 1 | 2018 | 32 | 0.18 | Why? |
| Myocardial Perfusion Imaging | 2 | 2018 | 218 | 0.18 | Why? |
| Capillaries | 1 | 2021 | 257 | 0.18 | Why? |
| Osteoarthritis | 2 | 2017 | 205 | 0.18 | Why? |
| Dose-Response Relationship, Drug | 4 | 2018 | 3776 | 0.18 | Why? |
| Naproxen | 1 | 2017 | 47 | 0.18 | Why? |
| Erythrocyte Volume | 1 | 2017 | 30 | 0.18 | Why? |
| Endothelin Receptor Antagonists | 2 | 2011 | 47 | 0.17 | Why? |
| Microvessels | 2 | 2019 | 490 | 0.17 | Why? |
| Rest | 1 | 2018 | 188 | 0.17 | Why? |
| Arrhythmias, Cardiac | 4 | 2018 | 2510 | 0.17 | Why? |
| Clinical Trials Data Monitoring Committees | 1 | 2017 | 58 | 0.16 | Why? |
| Humans | 71 | 2021 | 930598 | 0.16 | Why? |
| Macula Lutea | 1 | 2017 | 87 | 0.16 | Why? |
| Hypercholesterolemia | 1 | 2018 | 175 | 0.16 | Why? |
| Cardiomyopathy, Dilated | 1 | 2019 | 251 | 0.15 | Why? |
| Autonomic Nervous System | 1 | 2017 | 148 | 0.15 | Why? |
| Prospective Studies | 14 | 2019 | 43301 | 0.15 | Why? |
| Coronary Circulation | 1 | 2017 | 188 | 0.15 | Why? |
| Ibuprofen | 1 | 2017 | 156 | 0.15 | Why? |
| Cardiac Imaging Techniques | 1 | 2018 | 357 | 0.15 | Why? |
| Protective Agents | 1 | 2018 | 250 | 0.15 | Why? |
| Education, Professional | 1 | 2017 | 128 | 0.15 | Why? |
| Intravitreal Injections | 1 | 2017 | 347 | 0.15 | Why? |
| Critical Illness | 1 | 2019 | 17281 | 0.14 | Why? |
| Antihypertensive Agents | 3 | 2019 | 1962 | 0.14 | Why? |
| Ventricular Function, Right | 1 | 2018 | 388 | 0.13 | Why? |
| Adrenergic beta-Antagonists | 1 | 2018 | 465 | 0.13 | Why? |
| Coronary Stenosis | 1 | 2017 | 273 | 0.13 | Why? |
| Mitral Valve | 1 | 2017 | 342 | 0.13 | Why? |
| Ventricular Dysfunction, Right | 2 | 2019 | 639 | 0.13 | Why? |
| Cardiology Service, Hospital | 1 | 2020 | 602 | 0.13 | Why? |
| Pericardial Effusion | 1 | 2018 | 312 | 0.13 | Why? |
| Transportation of Patients | 1 | 2019 | 494 | 0.13 | Why? |
| Angiogenesis Inhibitors | 1 | 2017 | 395 | 0.13 | Why? |
| Cacao | 1 | 2012 | 16 | 0.13 | Why? |
| Shock, Cardiogenic | 2 | 2019 | 700 | 0.13 | Why? |
| Practice Guidelines as Topic | 4 | 2018 | 15421 | 0.12 | Why? |
| Stress, Physiological | 1 | 2017 | 378 | 0.12 | Why? |
| Rats, Inbred WKY | 1 | 2011 | 6 | 0.12 | Why? |
| Coronary Artery Bypass | 1 | 2019 | 629 | 0.12 | Why? |
| Male | 36 | 2021 | 367725 | 0.12 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 5277 | 0.12 | Why? |
| Death, Sudden, Cardiac | 1 | 2017 | 522 | 0.12 | Why? |
| Systole | 3 | 2018 | 252 | 0.12 | Why? |
| Retinal Diseases | 1 | 2018 | 441 | 0.12 | Why? |
| Superoxides | 1 | 2011 | 36 | 0.12 | Why? |
| Rats, Inbred SHR | 1 | 2011 | 58 | 0.12 | Why? |
| Imaging, Three-Dimensional | 1 | 2017 | 680 | 0.12 | Why? |
| Disease Progression | 4 | 2019 | 13580 | 0.12 | Why? |
| Endothelin-1 | 1 | 2011 | 69 | 0.11 | Why? |
| Vascular Cell Adhesion Molecule-1 | 1 | 2011 | 121 | 0.11 | Why? |
| Muscle Contraction | 1 | 2011 | 60 | 0.11 | Why? |
| Female | 35 | 2021 | 380317 | 0.11 | Why? |
| Nitric Oxide Synthase Type III | 1 | 2011 | 87 | 0.11 | Why? |
| Metabolic Diseases | 1 | 2017 | 505 | 0.11 | Why? |
| Cardiovascular Agents | 1 | 2017 | 663 | 0.11 | Why? |
| Muscle, Smooth, Vascular | 1 | 2011 | 86 | 0.11 | Why? |
| Survival Rate | 7 | 2018 | 9206 | 0.11 | Why? |
| Visual Acuity | 1 | 2017 | 790 | 0.11 | Why? |
| Coronary Angiography | 2 | 2018 | 2275 | 0.11 | Why? |
| Catecholamines | 2 | 2018 | 66 | 0.11 | Why? |
| Computed Tomography Angiography | 2 | 2018 | 2153 | 0.10 | Why? |
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 189 | 0.10 | Why? |
| Prognosis | 12 | 2020 | 32490 | 0.10 | Why? |
| Critical Pathways | 1 | 2020 | 1587 | 0.10 | Why? |
| Heart Ventricles | 1 | 2019 | 1139 | 0.10 | Why? |
| Cause of Death | 6 | 2020 | 4823 | 0.10 | Why? |
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2017 | 869 | 0.10 | Why? |
| Anemia | 1 | 2017 | 789 | 0.10 | Why? |
| Tomography, Optical Coherence | 1 | 2017 | 1008 | 0.10 | Why? |
| Feasibility Studies | 1 | 2019 | 3467 | 0.10 | Why? |
| Endothelial Cells | 1 | 2020 | 2048 | 0.10 | Why? |
| Middle Aged | 28 | 2021 | 270681 | 0.10 | Why? |
| Acute Coronary Syndrome | 2 | 2020 | 2107 | 0.09 | Why? |
| Cardiovascular Diseases | 3 | 2020 | 11497 | 0.09 | Why? |
| Treatment Outcome | 11 | 2020 | 51732 | 0.09 | Why? |
| Diagnostic Imaging | 1 | 2017 | 1044 | 0.09 | Why? |
| Heart Arrest | 1 | 2019 | 1239 | 0.09 | Why? |
| Hypertension, Pulmonary | 1 | 2017 | 970 | 0.09 | Why? |
| Analgesics | 1 | 2012 | 451 | 0.09 | Why? |
| Time Factors | 7 | 2019 | 31397 | 0.09 | Why? |
| Clinical Trials as Topic | 2 | 2018 | 7330 | 0.09 | Why? |
| Aged | 22 | 2021 | 215776 | 0.09 | Why? |
| Nitric Oxide | 2 | 2012 | 769 | 0.09 | Why? |
| Vascular Diseases | 1 | 2016 | 846 | 0.09 | Why? |
| Kaplan-Meier Estimate | 4 | 2018 | 4260 | 0.09 | Why? |
| Patient Education as Topic | 1 | 2017 | 1476 | 0.08 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.08 | Why? |
| Atrial Fibrillation | 2 | 2018 | 2320 | 0.08 | Why? |
| Arthritis, Rheumatoid | 2 | 2017 | 2043 | 0.08 | Why? |
| Injections, Intravenous | 2 | 2018 | 381 | 0.08 | Why? |
| Echocardiography | 5 | 2019 | 3661 | 0.08 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.08 | Why? |
| Multiple Organ Failure | 1 | 2017 | 1724 | 0.08 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.08 | Why? |
| Patient Admission | 2 | 2020 | 5250 | 0.08 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.08 | Why? |
| Reactive Oxygen Species | 1 | 2011 | 1136 | 0.07 | Why? |
| Noninvasive Ventilation | 1 | 2018 | 2329 | 0.07 | Why? |
| Oxygen | 1 | 2018 | 3715 | 0.07 | Why? |
| Diabetes Complications | 1 | 2017 | 2358 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2020 | 3892 | 0.07 | Why? |
| Heart Diseases | 2 | 2019 | 3503 | 0.07 | Why? |
| Cardiovascular System | 1 | 2012 | 750 | 0.07 | Why? |
| Pain | 1 | 2012 | 1084 | 0.07 | Why? |
| Influenza, Human | 2 | 2020 | 10779 | 0.07 | Why? |
| Aspirin | 1 | 2012 | 1043 | 0.07 | Why? |
| Hypoglycemic Agents | 1 | 2017 | 2165 | 0.07 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.07 | Why? |
| Immunohistochemistry | 1 | 2011 | 2275 | 0.07 | Why? |
| Ventricular Remodeling | 2 | 2017 | 349 | 0.07 | Why? |
| Rats | 1 | 2011 | 2764 | 0.06 | Why? |
| Forecasting | 1 | 2018 | 4492 | 0.06 | Why? |
| Heart Function Tests | 2 | 2019 | 101 | 0.06 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.06 | Why? |
| Phenylpropionates | 1 | 2002 | 68 | 0.06 | Why? |
| Sulfonamides | 1 | 2011 | 1294 | 0.06 | Why? |
| Caregivers | 1 | 2017 | 3112 | 0.06 | Why? |
| Percutaneous Coronary Intervention | 1 | 2019 | 3646 | 0.06 | Why? |
| Inpatients | 1 | 2018 | 5161 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2018 | 10649 | 0.06 | Why? |
| Renin-Angiotensin System | 2 | 2020 | 3661 | 0.06 | Why? |
| Hospitalization | 8 | 2020 | 54280 | 0.05 | Why? |
| Transplant Recipients | 1 | 2018 | 4982 | 0.05 | Why? |
| Pulmonary Embolism | 1 | 2020 | 4775 | 0.05 | Why? |
| Retrospective Studies | 8 | 2019 | 105322 | 0.05 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.05 | Why? |
| Influenza Vaccines | 1 | 2017 | 2941 | 0.05 | Why? |
| Biomedical Research | 2 | 2018 | 5270 | 0.05 | Why? |
| Hospital Mortality | 3 | 2019 | 22087 | 0.05 | Why? |
| Survival Analysis | 3 | 2019 | 7592 | 0.05 | Why? |
| Cells, Cultured | 1 | 2011 | 5835 | 0.05 | Why? |
| Microscopy, Fluorescence | 1 | 2021 | 335 | 0.05 | Why? |
| Natriuretic Peptide, Brain | 2 | 2017 | 1215 | 0.05 | Why? |
| Risk | 1 | 2012 | 5288 | 0.05 | Why? |
| Cell Respiration | 1 | 2018 | 26 | 0.05 | Why? |
| Internet | 1 | 2017 | 6204 | 0.05 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.05 | Why? |
| Autopsy | 2 | 2020 | 3495 | 0.05 | Why? |
| Coronary Vasospasm | 1 | 2018 | 36 | 0.05 | Why? |
| Hypotension | 2 | 2017 | 392 | 0.04 | Why? |
| Pulse Wave Analysis | 1 | 2019 | 221 | 0.04 | Why? |
| Peptic Ulcer Hemorrhage | 1 | 2017 | 24 | 0.04 | Why? |
| Water-Electrolyte Imbalance | 1 | 2018 | 119 | 0.04 | Why? |
| Software Design | 1 | 2017 | 87 | 0.04 | Why? |
| Microscopy, Electron | 1 | 2020 | 830 | 0.04 | Why? |
| Recovery of Function | 2 | 2018 | 2461 | 0.04 | Why? |
| Puerperal Disorders | 1 | 2019 | 151 | 0.04 | Why? |
| Myocardium | 2 | 2020 | 2323 | 0.04 | Why? |
| Risk Factors | 7 | 2020 | 71621 | 0.04 | Why? |
| Vasodilation | 1 | 2019 | 258 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Myocardial Revascularization | 1 | 2019 | 267 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2020 | 1115 | 0.04 | Why? |
| Peptide Fragments | 2 | 2017 | 2075 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| China | 2 | 2020 | 50654 | 0.04 | Why? |
| Echocardiography, Doppler | 1 | 2018 | 269 | 0.04 | Why? |
| Pregnancy Complications, Cardiovascular | 1 | 2019 | 231 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.04 | Why? |
| Adrenomedullin | 1 | 2017 | 217 | 0.04 | Why? |
| Adult | 8 | 2020 | 244371 | 0.04 | Why? |
| Prosthesis Design | 1 | 2018 | 594 | 0.04 | Why? |
| Confidence Intervals | 1 | 2017 | 744 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2017 | 6543 | 0.04 | Why? |
| Placebos | 1 | 2018 | 629 | 0.03 | Why? |
| Reference Values | 1 | 2017 | 795 | 0.03 | Why? |
| Pyrimidines | 1 | 2002 | 1557 | 0.03 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.03 | Why? |
| Protein Precursors | 1 | 2017 | 425 | 0.03 | Why? |
| Plaque, Atherosclerotic | 1 | 2018 | 423 | 0.03 | Why? |
| Patient Discharge | 2 | 2020 | 5696 | 0.03 | Why? |
| Blood Pressure Determination | 1 | 2017 | 450 | 0.03 | Why? |
| Electrocardiography | 2 | 2018 | 3957 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.03 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.03 | Why? |
| Terminology as Topic | 1 | 2018 | 546 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2017 | 9537 | 0.03 | Why? |
| Exercise Test | 1 | 2018 | 911 | 0.03 | Why? |
| Postoperative Care | 1 | 2017 | 755 | 0.03 | Why? |
| Myocytes, Cardiac | 1 | 2018 | 804 | 0.03 | Why? |
| Troponin T | 1 | 2017 | 771 | 0.03 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.03 | Why? |
| Iron | 1 | 2017 | 619 | 0.03 | Why? |
| Algorithms | 2 | 2018 | 7346 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Sex Distribution | 1 | 2018 | 2083 | 0.03 | Why? |
| Propensity Score | 1 | 2019 | 2690 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Ventricular Dysfunction, Left | 1 | 2019 | 993 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.03 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.03 | Why? |
| Cardiac Catheterization | 1 | 2017 | 882 | 0.03 | Why? |
| Denmark | 1 | 2017 | 2654 | 0.02 | Why? |
| Cardiomyopathies | 1 | 2019 | 997 | 0.02 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.02 | Why? |
| Waiting Lists | 1 | 2018 | 1388 | 0.02 | Why? |
| Polyphenols | 1 | 2012 | 283 | 0.02 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 1510 | 0.02 | Why? |
| Age Distribution | 1 | 2018 | 3567 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Netherlands | 1 | 2017 | 3533 | 0.02 | Why? |
| Flavonoids | 1 | 2012 | 492 | 0.02 | Why? |
| Blood Coagulation | 1 | 2020 | 2768 | 0.02 | Why? |
| Animals | 2 | 2020 | 78931 | 0.02 | Why? |
| Aftercare | 1 | 2017 | 1637 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.02 | Why? |
| Liver | 1 | 2020 | 4007 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Hospitals, University | 1 | 2017 | 4173 | 0.02 | Why? |
| Serine Endopeptidases | 1 | 2021 | 4606 | 0.02 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.02 | Why? |
| Patient Care Team | 1 | 2018 | 3556 | 0.02 | Why? |
| Risk Assessment | 2 | 2019 | 25439 | 0.02 | Why? |
| Biomarkers | 2 | 2017 | 23361 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Global Health | 2 | 2018 | 13911 | 0.02 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.02 | Why? |
| Receptor, Endothelin A | 1 | 2002 | 13 | 0.02 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.01 | Why? |
| Antioxidants | 1 | 2012 | 1593 | 0.01 | Why? |
| Patient Safety | 1 | 2017 | 4885 | 0.01 | Why? |
| Vascular Resistance | 1 | 2002 | 148 | 0.01 | Why? |
| Ventricular Fibrillation | 1 | 2002 | 126 | 0.01 | Why? |
| Stroke | 2 | 2017 | 8839 | 0.01 | Why? |
| Lung | 2 | 2020 | 31049 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2019 | 53120 | 0.01 | Why? |
| Myocardial Infarction | 1 | 2017 | 3361 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.01 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Kidney Transplantation | 1 | 2020 | 5397 | 0.01 | Why? |
| Nervous System Diseases | 1 | 2018 | 4092 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.01 | Why? |
| Triage | 1 | 2018 | 7151 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2017 | 48226 | 0.01 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.01 | Why? |
| Drug Eruptions | 1 | 2002 | 319 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| United Kingdom | 1 | 2017 | 18046 | 0.01 | Why? |
| Pregnancy | 1 | 2019 | 23879 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Mental Disorders | 1 | 2018 | 6742 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Headache | 1 | 2002 | 2257 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Chronic Disease | 1 | 2002 | 5139 | 0.01 | Why? |